Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$7.28 USD
+0.32 (4.60%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $7.27 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Actinium Pharmaceuticals (ATNM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.60 | $50.00 | $11.60 | 267.82% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Actinium Pharmaceuticals comes to $25.60. The forecasts range from a low of $11.60 to a high of $50.00. The average price target represents an increase of 267.82% from the last closing price of $6.96.
Analyst Price Targets (6 )
Broker Rating
Actinium Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ATNM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/17/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
5/14/2024 | Stephens | Sudan Loganathan | Not Available | Strong Buy |
4/1/2024 | B. Riley Securities | Yuan Zhi | Strong Buy | Strong Buy |
4/1/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
3/19/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
9/6/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $25.60 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -0.48 |